Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sentinel Oncology Limited currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, Ernesto Valle, who is also identified as the busiest examiner for the portfolio. The prosecution activity is concentrated within 1 distinct art unit. With 1 pending office action assigned to Ernesto Valle, the portfolio shows a highly focused distribution of work.
Practitioners should note that the involvement of only 1 distinct examiner and 1 distinct art unit simplifies the tracking of prosecution trends. Because there is only 1 pending office action, the examiner's individual statistics and the specific practices of the single art unit will be the primary factors influencing the portfolio's immediate outcomes. This centralized structure allows for a more predictable interaction with the patent office compared to portfolios spread across multiple units. The focus on the Biotechnology & Pharmaceuticals area indicates that the company's current intellectual property efforts are specialized within this specific field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17754200 | PHARMACEUTICAL COMPOUNDS | VALLE, ERNESTO | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17754200 | PHARMACEUTICAL COMPOUNDS | VALLE, ERNESTO | 33d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17754200 | PHARMACEUTICAL COMPOUNDS | VALLE, ERNESTO | 1623 | §103§112 | Final Rejection | 33d | Pending | Mar 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial